DrugPatentWatch Database Preview
Celgene Corp Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for CELGENE CORP, and when can generic versions of CELGENE CORP drugs launch?
CELGENE CORP has one approved drug.
There are six US patents protecting CELGENE CORP drugs.
There are eighty-eight patent family members on CELGENE CORP drugs in thirty-six countries.
Summary for Celgene Corp
| International Patents: | 88 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 4 |
| Patent Litigation for Celgene Corp: | See patent lawsuits for Celgene Corp |
| PTAB Cases with Celgene Corp as patent owner: | See PTAB cases with Celgene Corp as patent owner |
Drugs and US Patents for Celgene Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-001 | Aug 1, 2017 | RX | Yes | No | 9,732,062 | Start Trial | Y | Start Trial | |||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-001 | Aug 1, 2017 | RX | Yes | No | 10,610,125 | Start Trial | Start Trial | ||||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | 9,512,107 | Start Trial | Y | Y | Start Trial | ||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | 10,610,125 | Start Trial | Start Trial | ||||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-001 | Aug 1, 2017 | RX | Yes | No | 9,512,107 | Start Trial | Y | Y | Start Trial | ||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | 10,294,215 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Celgene Corp Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2010223919 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2010105243 | Start Trial |
| Taiwan | I653228 | Start Trial |
| Serbia | 57401 | Start Trial |
| Eurasian Patent Organization | 201491330 | Start Trial |
| Nicaragua | 201600022 | Start Trial |
| Singapore | 10201602862R | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
